Trial · NCT00585169
Memantine Treatment Study of Pathological Gambling
NCT00585169, Phase 2, Completed, Yale University; results first posted 2013-04-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Memantine Treatment Study of Pathological Gambling. Trials, record NCT00585169. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00585169
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Memantine Treatment Study of Pathological Gambling
- NCT number
- NCT00585169
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 29 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Pathological Gambling
- Interventions
- Memantine Hydrochloride
- First posted
- 2008-01-03
- Last updated
- 2013-04-08
- Results first posted
- 2013-04-08
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) | Baseline to study end point (10 weeks) | The PGYBOCS is a reliable \& valid, 10-item, clinician administered scale that rates gambling symptoms within the last 7 days. The first 5 questions assess urges and thoughts associated with pathological gambling, and the last 5 questions assess the behavioral component of the disorder. Scores of 0 through 4 are assigned each item according to the severity of the response (0 = least severe response or none, 4 = most severe response or extreme)with a score ranging from 0-40. Each set of questions (1-5 and 6-10) can be totaled separately for the component score (urges/thoughts and behavioral) as well as together for a total score. A score of 0 indicates no problems while increasing scores indicate increasing severity of problems with gambling. PG-YBOCS is used to measure changes across time. A decreasing score indicates a possible positive response to the intervention. Total score at baseline was compared with the study end to determine if the intervention was efficacious. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) | Baseline to study end point (10 weeks) | All participants who completed at least one study visit were included in the analysis. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) | Memantine | Baseline | 21.8 | Standard Deviation 4.3 | units on a scale |
| Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) | Memantine | 10 weeks | 8.9 | Standard Deviation 7.2 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Memantine | 29 | |
| Overall Study | COMPLETED | Memantine | 28 | |
| Overall Study | NOT COMPLETED | Memantine | 1 |
Source ClinicalTrials.gov
Adverse events15
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Light-headed/dizzy | General disorders | Memantine 10mg | 2 | 29 | |
| other | Light-headed/dizzy | General disorders | Memantine 20mg | 4 | 24 | |
| other | Light-headed/dizzy | General disorders | Memantine 30mg | 2 | 16 | |
| other | Headache | General disorders | Memantine 10mg | 3 | 29 | |
| other | Headache | General disorders | Memantine 20mg | 0 | 24 | |
| other | Headache | General disorders | Memantine 30mg | 0 | 16 | |
| other | Lethargic or tired | General disorders | Memantine 10mg | 0 | 29 | |
| other | Lethargic or tired | General disorders | Memantine 20mg | 1 | 24 | |
| other | Lethargic or tired | General disorders | Memantine 30mg | 3 | 16 | |
| other | Decreased libido | General disorders | Memantine 10mg | 0 | 29 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Memantine 10mg | ||
| Total, all-cause mortality | Memantine 20mg | ||
| Total, all-cause mortality | Memantine 30mg | ||
| Total, other adverse events | Memantine 10mg | 5 | 29 |
| Total, other adverse events | Memantine 20mg | 6 | 24 |
| Total, other adverse events | Memantine 30mg | 8 | 16 |
| Total, serious adverse events | Memantine 10mg | 0 | 29 |
| Total, serious adverse events | Memantine 20mg | 0 | 24 |
| Total, serious adverse events | Memantine 30mg | 0 | 16 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20721537 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00585169
GET https://conductscience.org/api/trials/v1/NCT00585169/registered